Trial Profile
A randomized, double-blind, two arm, parallel, placebo controlled study of rimonabant 20 mg effect on high density lipoprotein kinetics in patients with abdominal obesity and additional cardiometabolic risk factors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms HDL TURNOVER
- Sponsors Sanofi
- 12 Jan 2009 Actual patient numbers added (n=64), as reported by Clinicaltrials.gov
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
- 05 Nov 2008 Status changed from recruiting to discontinued, as reportedby sanofi-aventis.